newsroom
$CODORNÍU · Codorníu stuck with high-inventory alcohol stock as GLP-1 reduces consumption
now playing · $CODORNÍU
$CODORNÍUbearish· medium· pospablo schffner
Codorníu stuck with high-inventory alcohol stock as GLP-1 reduces consumption
Spanish alcohol producer Codorníu (Foro Founders portfolio) holding excess high-proof inventory; GLP-1 adoption reduces alcohol cravings, making it bad time to sell. Alcohol giant…
$TUPCALbullish· high· pospablo schffner
Portfolio company pivoted to white-label GLP-1 subscription, 5 people doing tens of millions ARR
Tupcal pivoted from AI weight-loss tracker via WhatsApp to white-label Ozempic subscription model, went to US to validate, now doing tens of millions ARR with 5 people. Exemplifie…
Anthropic winning enterprise AI with coding focus and safety branding
Anthropic captures 40% of enterprise AI spend vs OpenAI's 27% by focusing exclusively on enterprise-first APIs and coding (Claude Code), leveraging constitutional AI safety brandi…
$GOOGL···neutral· mediumpablo schffner
Google invested $2B in Anthropic, now launching Fitbit Air to compete in health wearables with data play
Google is a key Anthropic investor ($2B) enabling multi-cloud strategy, but also launching Fitbit Air ($99, no subscription) targeting mass Android users with Google Health integr…
$AMZN···bullish· mediumpablo schffner
Amazon's $3B Anthropic investment and Trainium chips enable 70% margins via multi-cloud
Amazon invested $3B in Anthropic and provides cheaper Trainium chips vs Nvidia, allowing Anthropic multi-cloud flexibility and 70% margins. Anthropic can choose best price/perform…
$MSFT···neutral· lowpablo schffner
Microsoft's OpenAI/Azure lock-in creates opening for Anthropic's multi-cloud approach
OpenAI tied to Azure; Anthropic's multi-cloud flexibility (AWS, GCP, Azure) lets them optimize cost/performance. Microsoft also secured Pentagon deal after Anthropic refused.
$NVO···bullish· highpablo schffner
GLP-1 drugs creating structural shift: 25% of Americans on Ozempic/Wegovy, recurring revenue for life
GLP-1 agonists (Ozempic, Wegovy, Mounjaro) used by 25% of Americans heading to 35%, $250/month recurring for life with documented 15-20% weight loss and metabolic benefits. Disrup…
$LLY···bullish· highpablo schffner
Eli Lilly's Mounjaro/Zepbound capturing GLP-1 market share alongside Novo Nordisk
Eli Lilly's tirzepatide (Mounjaro/Zepbound) is the other major GLP-1/GIP dual agonist driving the metabolic drug wave, with same recurring revenue dynamics and market disruption a…
$OPENAIbearish· mediumdavid baratec
OpenAI losing enterprise share to Anthropic, trust issues with Sam Altman
OpenAI dispersed across consumer and enterprise, locked into Microsoft Azure, and Sam Altman's pivot from non-profit to for-profit plus opaque Pentagon deal erode trust. Enterpris…
Mythos frontier model finds 27-year-old vulnerabilities, 60% success on 32-step hacks in 6 weeks
Anthropic's unreleased Mythos model discovered zero-day vulnerabilities undetected for 27 years, achieving 3/10 to 6/10 success on 32-step attack chains in 6 weeks. Withheld from…
$WHOOPbullish· mediumdavid baratec
Whoop's elite-athlete-first B2B2C model drives $10B valuation with 2.5M users at $24/mo
Whoop targeted Navy SEALs, NFL, NBA first (banned by leagues creating viral marketing), no-screen subscription hardware ($0 device, $24/mo), 2.5M users, 15% churn in B2C, $600M AR…